ASND vs BBIO: stock comparison and AI forecast
Ascendis Pharma A/S (ASND) and Bridgebio Pharma, Inc. (BBIO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ASND Ascendis Pharma A/S
- Price
- $250.17 +11.0% · 6M
- Market Cap
- $16.43B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
BBIO Bridgebio Pharma, Inc.
- Price
- $74.03 +7.6% · 6M
- Market Cap
- $14.42B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ASND is 1.1 times larger than BBIO by market capitalization ($16.43B against $14.42B).
- Over the last six months ASND returned +11.0% and BBIO +7.6%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ASND | BBIO |
|---|---|---|
| Market Cap | $16.43B | $14.42B |
| EPS | $-15.40 | $-3.92 |
| Revenue/Share | $20.59 | $4.85 |
| FCF/Share | $-0.10 | $-1.90 |
Profitability & Margins
| Metric | ASND | BBIO |
|---|---|---|
| ROA | – | -26.2% |
| ROIC | -121.1% | -30.8% |
| Gross Margin | 86.1% | 94.3% |
| Operating Margin | -23.7% | -38.5% |
| Net Margin | – | -59.8% |
| EBT Margin | -33.4% | -67.9% |
| Tax Rate | -6.0% | 0.1% |
Financial Health
| Metric | ASND | BBIO |
|---|---|---|
| Current Ratio | 1.04x | 2.09x |
| Quick Ratio | 0.76x | 2.03x |
| Interest Coverage | – | -0.3x |
| Working Capital | $47M | $1.07B |
Cash Flow
| Metric | ASND | BBIO |
|---|---|---|
| Operating Cash Flow | -$2M | -$369M |
| Free Cash Flow | -$7M | -$370M |
| Capital Spending | -$5M | -$830K |
| FCF/Sales | -0.5% | -39.1% |
| CapEx/Sales | 0.3% | 0.1% |
Operational Efficiency
| Metric | ASND | BBIO |
|---|---|---|
| Asset Turnover | 0.92x | 0.44x |
| Receivables Turnover | – | 2.5x |
| Inventory Turnover | 0.6x | 0.9x |
| Fixed Assets Turnover | 8.1x | 187.5x |
| Days Sales Outstanding | – | 145 days |
| Days Inventory | 662 days | 407 days |
| Payables Period | – | 602 days |
| Cash Conversion Cycle | – | -50 days |
Income Statement
| Metric | ASND | BBIO |
|---|---|---|
| Total Revenue | $1.35B | $946M |
| Operating Income | -$320M | -$364M |
| Net Income | – | -$566M |
| R&D Expense | $599M | $536M |
| SG&A Expense | $884M | $709M |
| Cost of Goods Sold | $188M | $54M |
Dividend & Shareholder Information
| Metric | ASND | BBIO |
|---|---|---|
| Shares Outstanding | 66M | 195M |
ASND vs BBIO: stock comparison and AI forecast
Which is bigger, ASND or BBIO?
ASND is 1.1 times larger than BBIO by market capitalization ($16.43B against $14.42B).
Which stock performed better over the last six months, ASND or BBIO?
Over the last six months ASND returned +11.0% and BBIO +7.6%.
Which one does Intratio's AI model rank higher, ASND or BBIO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.